MILWAUKEE, April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ: LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its transaction with AbbVie.
Click here to learn how to join the or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
In the transaction, Landos shareholders will receive only $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million in the aggregate, subject to the achievement of a clinical development milestone. The transaction agreement unreasonably limits competing transactions for Landos by imposing a significant penalty if Landos accepts a competing bid. Landos insiders will receive substantial benefits as part of change of control arrangements.
Landos has filed a preliminary proxy statement seeking stockholder approval, which requires further investigation.
If you own Landos common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
